Table 2:

Univariate and multivariate analysis of association between ovarian cancer gene signatures and overall survival (OS) of patients in A) the TCGA dataset or B) the smaller MGH study.

Published gene signature		A) HGSOC tumors (TCGA, n=518)b				B) MGH Data (n=38)
Study	Signature or % stromal content	OS	b OS, adjust stage	b OS, adjust % stroma	b OS, adjust % stroma + stage	OS, gene expression in microdissected epithelium	OS, gene expression in microdissected stroma
AOCS C1 stroma vs. tumora	Stromal genes vs. tumor genes	0.0870	0.137	0.2730	0.484	0.2440	0.1800
MGH stroma vs. tumora	Tumor-associated stroma vs. tumor	0.0336	0.0544	0.148	0.289	0.555	0.156
MGH tissue- specific genesa	Tumor	0.778	0.640	0.996	0.906	0.924	0.718
	Tumor-associated stroma	0.0430	0.0732	0.177	0.337	0.540	0.164
	Normal or tumor-associated stroma	0.0395	0.0707	0.140	0.294	0.598	0.175
TCGA stromal content	Pathologist assessment of % stroma in TCGA samples	0.0979	0.0499	N/A	N/A	N/A	N/A
AOCS (Tothill et al.)	C1	0.0175	0.0658	0.0755	0.276	0.343	0.316
	PFS	0.0045	0.0195	0.0346	0.148	0.242	0.377
	OS	0.0010	0.0068	0.0076	0.0541	0.356	0.105
Bentink et al.	Angiogenic vs. non-angiogenic	0.0313	0.115	0.109	0.374	0.552	0.324
Bignotti et al.	Metastasis vs. primary	0.0165	0.0921	0.0613	0.311	0.383	0.229
Spentzos et al.	Prognosis	0.0118	0.0330	0.0507	0.163	0.608	0.145
Bonome et al.	Prognosis	0.0426	0.0571	0.128	0.208	0.366	0.0352
Biade et al.	Malignant vs. benign	0.310	0.266	0.587	0.584	0.642	0.101
Konstantinopoulos et al.	BRCA-like	0.0167	0.0281	0.0272	0.0386	0.696	0.387

Significance (p < 0.05) is highlighted in bold.

^aTable S2.

^bMultivariate survival analyses of TCGA data adjusted for percent stromal content and/or stage.